Happy Chinese New Year 2019!

Posted by Sandra Hageman on Feb 5, 2019 11:09:26 AM

新年快乐

Read More

Tags: Quality, Peace, Development, BioPharma, Chinese New Year, Year of the Pig

National Go Red Day

Posted by Jesse Gehris on Feb 1, 2019 12:30:00 PM

Today, at all four of our wholly-owned central laboratory testing facilities (United States, Netherlands, China, and Singapore), we at Eurofins Central Laboratory, a division of Eurofins BioPharma Services, wear red with the American Heart Association to aide in uniting the world from continent to continent in effort of bringing awareness to our friends, families, and colleagues suffering from cardiovascular-related diseases (CVD). Diseases under this remit include, but are not limited to, defects at birth, heart rhythm complications, and abnormal blood vessel conditions.

Read More

Tags: Quality, Results, Development, American Heart Month, Heart Disease, Healthy Lifestyle

World Leprosy Day

Posted by Jesse Gehris on Jan 27, 2019 9:00:00 AM

On January 27th,  Eurofins Central Laboratory recognizes World Leprosy Day with the World Health Organization (WHO). Also known as Hansen’s disease, Leprosy is a chronic infectious disease caused by Mycobacterium Leprae. This disease affects the skin, peripheral nerves, mucus membranes of the upper respiratory tract, and eyes. Individuals affected will experience sensory loss in these affected areas as well as damaged thickened nerves.

Read More

Tags: Central Laboratory, Drug Development, Bioanalytical Testing, BioPharma, Leprosy

Moebius Syndrome Awareness Day

Posted by Jesse Gehris on Jan 24, 2019 9:00:00 AM

Today we at Eurofins Central Laboratory recognize a rare neurological disorder known as Moebius Syndrome.

Read More

Tags: Central Laboratory, Clinical Trial, Bioanalytical Testing, Development, Science Education, BioPharma, Moebius Syndrome

Neurodegenerative Disease Treatments

Posted by Tracy Hendershott on Jan 14, 2019 9:00:00 AM

While we have numerous symptomatic treatments today, there is still no cure for neurodegenerative diseases such as Parkinson’s and Alzheimer’s. There are more than 600 neurodegenerative diseases alone that affect the brain, spine, and peripheral nervous system. While diseases like Parkinson’s affect motor functions, Alzheimer’s is a progressive disease that destroys memory and other mental functions.

Read More

Tags: Central Laboratory, BioPharma, Alzheimer's Disease, Neurodegenerative, Parkinson's Disease

Eurofins Central Laboratory Celebrates 30 Years of GLP

Posted by Sandra Hageman on Jan 7, 2019 9:00:00 AM

 

Celebrating Thirty Years of Good Laboratory Practice

The GLP (Good Laboratory Practice) Testing Facility of Eurofins Central Laboratory in Breda, The Netherlands has been accredited for OECD GLP for over 30 years. It all started at the BCO Centre for Research (B for Bergschot 71, the street address ever since) with the first inspection by the Dutch Health Care Inspectorate in June 1988. Over the years, BCO underwent several transformations and evolved into becoming one of the Eurofins Central Laboratory facilities, keeping the GLP Test Facility embedded in the Breda Clinical Laboratory.

Read More

Tags: Central Laboratory, Quality, Results, Bioanalytical Testing, BioPharma

Cervical Health Awareness Month

Posted by Jesse Gehris on Jan 3, 2019 2:00:00 PM

Throughout the month, Eurofins Central Laboratory, a member of Eurofins BioPharma Services, stands with the American Cancer Society to recognize January as Cervical Cancer Awareness Month. According to the World Health Organization (WHO):

Read More

Tags: Central Laboratory, Clinical Trial, Bioanalytical Testing, Development, Cervical Cancer

FDA Approves New Treatment for Adult Patients With Rare, Life-Threatening Blood Disease (PNH)

Posted by Tracy Hendershott on Dec 24, 2018 9:00:00 AM

At Eurofins BioPharma Services, we feel this FDA press release, as a Christmas gift that came early! After working on multiple protocols, across multiple clients, we couldn't be happier to see the continued evolution of treatment solutions for this rare disease (around 2 cases per million). Prior to the first treatment being released in 2007, life expectancy of patient diagnosed with PNH was only ten years, with poor quality of life throughout that time. With the significant resource dedication of years of effort and capital, our peers and colleagues throughout the clinical trial industry have allowed patients to have:

Read More

Tags: FDA, Central Laboratory, Clinical Trial, PNH, New Treatment

Compound Screening & Cellular Response Evaluation Improvements

Posted by Tracy Hendershott on Dec 4, 2018 9:00:00 AM

We would like to congratulate our colleagues at Eurofins DiscoverX for their recent patent application approval for improvements to compound screening and evaluation on cellular responses.

Read More

Tags: Cellular Response, DiscoverX, Compound Screening

Stress Urinary Incontinence

Posted by Tracy Hendershott on Nov 27, 2018 9:00:00 AM

Currently, there aren't any globally-approved pharmaceutical treatments for Stress Urinary Incontinence (SUI). With a predominately female patient population ranging in the hundreds of millions of people worldwide, this provides them with only surgical and physical therapy-based options, limiting their choice of solutions. While effective for some, there can be challenges that come with the invasive nature of surgical procedures, as well as non-compliance with the length of time required for successful physical therapy outcomes. 

Read More

Tags: Pharmaceutical, BioPharma, Stress Urinary Incontinence